Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2843

The Business Research Company offers in-depth market insights through Acute Agitation And Aggression Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The acute agitation & aggression treatment market size has grown strongly in recent years. It will grow from $5.4 billion in 2023 to $5.72 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to advances in pharmacology, rise in clinical research, regulatory approvals, rise in prevalence of acute agitation and aggression cases, increased awareness regarding mental health .

The acute agitation & aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.23 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to growing aging population, growing healthcare infrastructure, rising pharmaceutical industry investment, rise in home-base care, rise in disposable income. Major trends in the forecast period include non-pharmacological interventions, precision medicine, ai and predictive analytics, community-based support, industry collaboration.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp

Market Segmentation:
The main types of acute agitation and aggression treatments are behavioral approaches, environmental interventions, and pharmacologic approaches. The behavioral approach refers to a psychological perspective that emphasizes the scientific study of observable behavior and its environmental determinants. It includes various drugs such as anti-psychotics, benzodiazepines, and others, and is taken through a variety of routes of administration, including oral, intramuscular and others. These are used in treating various indications such as schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation and aggression, alcohol withdrawal and others, by multiple end-users such as hospitals and ambulatory surgical centers, psychiatric care facilities and others.

Major Driver - Rising Dementia Incidence Fuels Growth In Acute Agitation And Aggression Treatment Market
The increase in the incidence of dementia is expected to propel the growth of the acute agitation and aggression treatment market going forward. Dementia refers to conditions characterized by impaired memory, cognition, and the capability to manage everyday tasks. A symptom often observed in dementia patients is agitation, manifested through behaviors such as restlessness, repetitive actions, or frequent hand movements. Acute agitation and aggression treatment play a key role in dementia. It reduces the risk of harmful symptoms, improves the patient's quality of life, and manages the underlying cause of the agitation. For instance, in February 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, it was projected that about 401,300 Australians have dementia, and this figure is anticipated to be doubled to reach 849,300 in 2058. Therefore, the increase in the incidence of dementia is driving the growth of the acute agitation and aggression treatment market.

Competitive Landscape:
Major companies operating in the acute agitation and aggression treatment market market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd, AstraZeneca PLC, Ono Pharmaceutical Co Ltd, Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc, Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/acute-agitation-and-aggression-treatment-global-market-report

Top Trend - Innovative Sublingual Film Igalmi (Dexmedetomidine) Revolutionizes Acute Agitation Treatment Market
Major companies operating in the acute agitation and aggression treatment market are developing innovative products and getting approved, such as IGALMI (dexmedetomidine), to provide a new treatment option for patients with agitation associated with schizophrenia or bipolar disorder. IGALMI (dexmedetomidine) is a sublingual film used to treat acute agitation associated with schizophrenia or bipolar I or II disorder in adults. For instance, in April 2022, BioXcel Therapeutics Inc., a US-based biopharmaceutical company, received IGALMI (dexmedetomidine) approval from the Food and Drug Administration. It is a quick-acting drug that starts working in a matter of minutes. It is also a short-acting medication, with effects lasting for about 2 hours. It can significantly improve existing therapies for a severe or life-threatening condition.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Acute Agitation And Aggression Treatment Market Characteristics
3. Acute Agitation And Aggression Treatment Market Trends And Strategies
4. Acute Agitation And Aggression Treatment Market - Macro Economic Scenario
5. Acute Agitation And Aggression Treatment Market Size And Growth
…..
27. Acute Agitation And Aggression Treatment Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.